SUPR October 2021 Newsletter
IDHS/SUPR Trainings: The Illinois Department of Human Services/Division of Substance Use Prevention and Recovery (IDHS/SUPR) invites you to participate in IDHS/SUPR sponsored trainings. IDHS/SUPR is pleased to announce the second quarter training opportunities for treatment organizations, including opioid treatment programs and recovery homes.
To learn more about the training offerings, please review the attached training calendar for descriptions, date(s), and time(s) for each training. We have also included “Instructions for Registering for IDHS/SUPR Trainings” that outlines how to register for the trainings. Please note that Prevention First coordinates these trainings.
SUPR/Bureau of Prevention Services (BPS) Budget Revisions: October is here which means it is budget revision request time for grantees of BPS. Please keep in mind that you will need to include the completed Budget template (attached) in the request and a small explanation in the narrative sections regarding the reason for the specific category/line item adjustment. If you need to revise your SFY22 approved budget, please reach out to your Project Director or Administrator.
Strategic Prevention Framework Rx Grant: The Illinois Department of Human Services/ Division of Substance Use Prevention and Recovery (IDHS/SUPR) have been granted the Strategic Prevention Framework Rx grant. SUPR will be working with Midwestern University as well as the Prescription Monitoring Program (PMP) to provide prevention awareness activities in selected high schools. Communities and high schools will be chosen by PMP data that identify areas where prescription drug prescribing for emerging adults is high. SUPR is looking forward to a great project with exceptional partners.
Increases in Availability of Cannabis Products Containing Delta-8 THC: This highlight is from the CDC Health Alert Network CDCHAN-00451. There is an increased availability of cannabis products containing delta-8 tetrahydrocannabinol (THC) and the potential for adverse events due to insufficient labeling of products containing THC and cannabidiol (CBD). From January 1 to July 31, 2021, after The American Association of Poison Control Centers (AAPCC) introduced a product code specific to delta-8 THC into its National Poison Data System (NPDS), 660 delta-8 THC exposures were recorded with the new product code, and one additional case was recoded as a delta-8 THC exposure from October 2020.
Eighteen percent of exposures (119 of 661 cases) required hospitalization, and 39% (258 of 661 cases) involved pediatric patients less than 18 years of age. Delta-8 THC intoxication can cause adverse effects similar to those observed during delta-9 THC intoxication, and may include lethargy, uncoordinated movements and decreased psychomotor activity, slurred speech, increased heart rate progressing to slowed heart rate, low blood pressure, difficulty breathing, sedation, coma. See attached newsletter for more information from the CDC.
Click here to view the full newsletter.